Report Detail
Global Waldenstrom Macroglobulinemia Therapeutics Market Insights, Forecast to 2025
- RnM2923636 |
- 18 February, 2019 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
The global Waldenstrom Macroglobulinemia Therapeutics market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Waldenstrom Macroglobulinemia Therapeutics market based on company, product type, end user and key regions.
This report studies the global market size of Waldenstrom Macroglobulinemia Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Waldenstrom Macroglobulinemia Therapeutics in these regions.
This research report categorizes the global Waldenstrom Macroglobulinemia Therapeutics market by top players/brands, region, type and end user. This report also studies the global Waldenstrom Macroglobulinemia Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
BeiGene(Beijing) Co.,Ltd
Calithera Biosciences, Inc.
Celgene Corporation
Genentech, Inc.
Genmab A/S
Gilead Sciences, Inc.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IGF Oncology, LLC.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Market size by Product
CB-839
Copanlisib Hydrochloride
DI-B4
Entospletinib
Everolimus
FV-162
Others
Market size by End User
Clinic
Hospital
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Waldenstrom Macroglobulinemia Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Waldenstrom Macroglobulinemia Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Waldenstrom Macroglobulinemia Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Waldenstrom Macroglobulinemia Therapeutics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Waldenstrom Macroglobulinemia Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Waldenstrom Macroglobulinemia Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Waldenstrom Macroglobulinemia Therapeutics Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate by Product
- 1.4.2 CB-839
- 1.4.3 Copanlisib Hydrochloride
- 1.4.4 DI-B4
- 1.4.5 Entospletinib
- 1.4.6 Everolimus
- 1.4.7 FV-162
- 1.4.8 Others
- 1.5 Market by End User
- 1.5.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate by End User
- 1.5.2 Clinic
- 1.5.3 Hospital
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size
- 2.1.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue 2014-2025
- 2.1.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales 2014-2025
- 2.2 Waldenstrom Macroglobulinemia Therapeutics Growth Rate by Regions
- 2.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Regions
- 2.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Waldenstrom Macroglobulinemia Therapeutics Sales by Manufacturers
- 3.1.1 Waldenstrom Macroglobulinemia Therapeutics Sales by Manufacturers
- 3.1.2 Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Manufacturers
- 3.1.3 Global Waldenstrom Macroglobulinemia Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Waldenstrom Macroglobulinemia Therapeutics Revenue by Manufacturers
- 3.2.1 Waldenstrom Macroglobulinemia Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.3 Waldenstrom Macroglobulinemia Therapeutics Price by Manufacturers
- 3.4 Waldenstrom Macroglobulinemia Therapeutics Manufacturing Base Distribution, Product Types
- 3.4.1 Waldenstrom Macroglobulinemia Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Waldenstrom Macroglobulinemia Therapeutics Product Type
- 3.4.3 Date of International Manufacturers Enter into Waldenstrom Macroglobulinemia Therapeutics Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Product
- 4.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Product
- 4.3 Waldenstrom Macroglobulinemia Therapeutics Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Waldenstrom Macroglobulinemia Therapeutics Breakdown Data by End User
6 North America
- 6.1 North America Waldenstrom Macroglobulinemia Therapeutics by Countries
- 6.1.1 North America Waldenstrom Macroglobulinemia Therapeutics Sales by Countries
- 6.1.2 North America Waldenstrom Macroglobulinemia Therapeutics Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Waldenstrom Macroglobulinemia Therapeutics by Product
- 6.3 North America Waldenstrom Macroglobulinemia Therapeutics by End User
7 Europe
- 7.1 Europe Waldenstrom Macroglobulinemia Therapeutics by Countries
- 7.1.1 Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Countries
- 7.1.2 Europe Waldenstrom Macroglobulinemia Therapeutics Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Waldenstrom Macroglobulinemia Therapeutics by Product
- 7.3 Europe Waldenstrom Macroglobulinemia Therapeutics by End User
8 Asia Pacific
- 8.1 Asia Pacific Waldenstrom Macroglobulinemia Therapeutics by Countries
- 8.1.1 Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales by Countries
- 8.1.2 Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Waldenstrom Macroglobulinemia Therapeutics by Product
- 8.3 Asia Pacific Waldenstrom Macroglobulinemia Therapeutics by End User
9 Central & South America
- 9.1 Central & South America Waldenstrom Macroglobulinemia Therapeutics by Countries
- 9.1.1 Central & South America Waldenstrom Macroglobulinemia Therapeutics Sales by Countries
- 9.1.2 Central & South America Waldenstrom Macroglobulinemia Therapeutics Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Waldenstrom Macroglobulinemia Therapeutics by Product
- 9.3 Central & South America Waldenstrom Macroglobulinemia Therapeutics by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics by Countries
- 10.1.1 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales by Countries
- 10.1.2 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics by Product
- 10.3 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics by End User
11 Company Profiles
- 11.1 BeiGene(Beijing) Co.,Ltd
- 11.1.1 BeiGene(Beijing) Co.,Ltd Company Details
- 11.1.2 Company Business Overview
- 11.1.3 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.1.5 BeiGene(Beijing) Co.,Ltd Recent Development
- 11.2 Calithera Biosciences, Inc.
- 11.2.1 Calithera Biosciences, Inc. Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.2.5 Calithera Biosciences, Inc. Recent Development
- 11.3 Celgene Corporation
- 11.3.1 Celgene Corporation Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.3.5 Celgene Corporation Recent Development
- 11.4 Genentech, Inc.
- 11.4.1 Genentech, Inc. Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.4.5 Genentech, Inc. Recent Development
- 11.5 Genmab A/S
- 11.5.1 Genmab A/S Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.5.5 Genmab A/S Recent Development
- 11.6 Gilead Sciences, Inc.
- 11.6.1 Gilead Sciences, Inc. Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.6.5 Gilead Sciences, Inc. Recent Development
- 11.7 Hutchison MediPharma Limited
- 11.7.1 Hutchison MediPharma Limited Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.7.5 Hutchison MediPharma Limited Recent Development
- 11.8 Idera Pharmaceuticals, Inc.
- 11.8.1 Idera Pharmaceuticals, Inc. Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.8.5 Idera Pharmaceuticals, Inc. Recent Development
- 11.9 IGF Oncology, LLC.
- 11.9.1 IGF Oncology, LLC. Company Details
- 11.9.2 Company Business Overview
- 11.9.3 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.9.5 IGF Oncology, LLC. Recent Development
- 11.10 Incyte Corporation
- 11.10.1 Incyte Corporation Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Products Offered
- 11.10.5 Incyte Corporation Recent Development
- 11.11 Karyopharm Therapeutics, Inc.
- 11.12 Merck KGaA
- 11.13 Millennium Pharmaceuticals, Inc.
12 Future Forecast
- 12.1 Waldenstrom Macroglobulinemia Therapeutics Market Forecast by Regions
- 12.1.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Regions 2019-2025
- 12.1.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Forecast by Regions 2019-2025
- 12.2 Waldenstrom Macroglobulinemia Therapeutics Market Forecast by Product
- 12.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales Forecast by Product 2019-2025
- 12.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Forecast by Product 2019-2025
- 12.3 Waldenstrom Macroglobulinemia Therapeutics Market Forecast by End User
- 12.4 North America Waldenstrom Macroglobulinemia Therapeutics Forecast
- 12.5 Europe Waldenstrom Macroglobulinemia Therapeutics Forecast
- 12.6 Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Forecast
- 12.7 Central & South America Waldenstrom Macroglobulinemia Therapeutics Forecast
- 12.8 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Waldenstrom Macroglobulinemia Therapeutics Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Waldenstrom Macroglobulinemia Therapeutics . Industry analysis & Market Report on Waldenstrom Macroglobulinemia Therapeutics is a syndicated market report, published as Global Waldenstrom Macroglobulinemia Therapeutics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Waldenstrom Macroglobulinemia Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
